Using stem cells from umbilical cords to treat systemic sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) in patients with systemic sclerosis (SSc). It is a single-center, randomized, double-blind, placebo-controlled study involving 18 patients, who will be divided into three groups: one receiving a placebo, one receiving one infusion of UCMSC, and another receiving two infusions. The trial will monitor for treatment-related severe adverse events (TRSAE) before proceeding with subsequent patient blocks. The goal is to determine if UCMSC can provide therapeutic benefits for individuals suffering from this severe autoimmune condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. SSc according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2103 classification criteria for systemic sclerosis
2. Severe disease defined as:

   i) disease duration of 2 years or less with an mRss of \> 20 and (ESR \> 25 mm and/or hemoglobin \< 11 g/dL, not explained by other causes than SSc), or ii) mRss \>15 without any restriction as to disease duration plus at least one major organ involvement as defined by: a) respiratory involvement consisting of lung diffusion capacity for carbon monoxide (DLCO) and/or forced vital capacity (FVC) \< 80% predicted and evidence of interstitial lung disease (chest X-ray and/or high resolution computed tomography (HRCT) scan); b) renal involvement consisting of past renal crisis and/or stage 2 or 3 chronic kidney disease (glomerular filtration rate between 30-89 mL/min) not explained by other causes than SSc; c) cardiac involvement consisting of reversible congestive heart failure, atrial or ventricular rhythm disturbances such as recurrent episodes of atrial fibrillation or flutter, recurrent atrial paroxysmal tachycardia, conduction abnormalities (2nd or 3rd degree atrioventricular block), and/or mild to moderate pericardial effusion. All causes of organ involvement should be attributed to SSc.
3. Inadequate response (determined by patient and physician judgement) or adverse events necessitating discontinuation of standard therapy (usually consisting of methotrexate 25 mg subcutaneous (or as tolerated) per week and/or mycophenolate mofetil 2-3 gm/d (or as tolerated) for at least 3 months
4. Ineligibility or unwillingness to undergo autologous hematopoietic stem cell transplant

Exclusion Criteria:

1. Age \< 18 years
2. Pregnancy or unwillingness to use adequate contraception
3. Life-threatening end-organ damage defined as:

   * FVC \< 45% and/or DLCO (corrected for hemoglobin) \< 30% predicted;
   * Left ventricular ejection fraction \< 40% by cardiac echocardiography;
   * Pulmonary hypertension with baseline resting systolic pulmonary arterial pressures \> 50 mmHg by cardiac echocardiography, or mean pulmonary artery pressure \> 25 mmHg (and pulmonary wedge pressure \< 15 mmHg) on right heart catheterization;
   * stage 4 or more chronic kidney disease (glomerular filtration rate \< 30 ml/min)
4. Liver failure defined as an abnormal transaminase level (aspartate aminotransferase (ASAT), alanine aminotransaminase (ALAT) \> 3 normal) unless related to activity of the disease
5. Concurrent neoplasms or myelodysplasia
6. Uncontrolled hypertension
7. Uncontrolled acute or chronic infection (HIV, HTLV-1/2 (Human T-lymphotropic virus), hepatitis B surface Ag positive, hepatitis C positive) or high risk thereof
8. Significant malnutrition with BMI \< 18 kg/m2
9. Severe concomitant psychiatric disorder
10. Bone marrow insufficiency defined as neutropenia \< 0.5 x 109 cell/L, thrombocytopenia \< 30 x 109 cell/L, anemia \< 8g/dL, CD4+ T lymphopenia \< 200 x 106 cell/L due to other diseases than SSc (CD4 - cluster of differentiation 4)
11. History of poor compliance
12. Concurrent enrolment in any other protocol using an investigational drug
13. Inability to provide informed consent

Where it's running

• Sir Mortimer B. Davis Jewish General Hospital
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Marie Hudson, MD — Sir Mortimer B. Davis - Jewish General Hospital
• Study coordinator: Marie Hudson, MD
• Email: marie.hudson@mcgill.ca
• Phone: 514-340-8222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Systemic Sclerosis Patient Cohort: Longitudinal Observation at Peking University Third Hospital

  This observational study follows people with systemic sclerosis to understand how the disease progresses and to identify markers and potential targets for treatment.

  Recruiting Peking University Third Hospital · Beijing · NCT07836361

• Brachytherapy and Nivolumab Before Surgery for Rectal Cancer

  This small Phase II study tests whether targeted internal radiation therapy followed by two doses of nivolumab can be safely given before rectal cancer surgery to see if it helps the treatment work.

  Recruiting Phase 2 Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec · NCT07645118

• New nerve surgery to help men regain erections after prostate cancer surgery

  This study will try a new nerve graft surgery using the ilioinguinal nerve to help men who lost erections after prostate removal regain erectile function within a year.

  Recruiting Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec · NCT07188064

• Long-term safety of nipple sparing mastectomy for women with genetic breast cancer risk

  This study is testing the long-term safety of nipple-sparing mastectomy for women with a genetic risk of breast cancer to see if it’s a good option for those who want to keep their nipple area.

  Recruiting at 9 sites Sir Mortimer B. Davis - Jewish General Hospital · New Haven, Connecticut and 15 other locations · NCT06888388

• Nerve grafting technique to help preserve erectile function after prostate surgery

  This study is testing a new nerve grafting technique during prostate surgery to see if it can help men keep their erectile function after the operation.

  Recruiting at 2 sites Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec and 1 other locations · NCT06521710

• Detecting and profiling measurable residual disease in multiple myeloma patients

  This study is testing a new way to check for leftover cancer cells in multiple myeloma patients who are in remission after a transplant to see how well their treatment is working.

  Recruiting Sir Mortimer B. Davis - Jewish General Hospital · Montreal, Quebec · NCT05530096

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.